<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Reduced-intensity conditioning has extended the use of allogeneic hematopoietic stem cell transplantation (HSCT) to patients otherwise not eligible for this treatment due to older age or frailty </plain></SENT>
<SENT sid="1" pm="."><plain>One hundred twelve <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo>/<z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> patients received fludarabine and melphalan (FM) conditioning with allogeneic HSCT </plain></SENT>
<SENT sid="2" pm="."><plain>Most patients (73%) were not in remission </plain></SENT>
<SENT sid="3" pm="."><plain><z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">Graft-versus-host disease</z:e> (GVHD) prophylaxis consisted of tacrolimus and mini-<z:chebi fb="0" ids="44185">methotrexate</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>Median age was 55 years (range, 22-74) </plain></SENT>
<SENT sid="5" pm="."><plain>Donors were related (53%) and unrelated (47%) </plain></SENT>
<SENT sid="6" pm="."><plain>Median follow-up of surviving patients (n = 43) was 29.4 months (range, 13.1-87.7) </plain></SENT>
<SENT sid="7" pm="."><plain>The complete remission (CR) rate was 82% </plain></SENT>
<SENT sid="8" pm="."><plain>Estimates of 2-year survival were 66%, 40%, and 23% for patients in CR, with active disease without and with circulating blasts at HSCT, respectively </plain></SENT>
<SENT sid="9" pm="."><plain>In multivariate analysis, survival was negatively influenced by active disease at HSCT and development of grade II-IV <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD </plain></SENT>
<SENT sid="10" pm="."><plain>Presence of circulating blasts at HSCT negatively influenced freedom from disease progression </plain></SENT>
<SENT sid="11" pm="."><plain>Incidence of nonrelapse mortality (NRM) was significantly higher for patients with active disease, but was not influenced by patient age </plain></SENT>
<SENT sid="12" pm="."><plain>Patients in CR had a day-100 and 2-year NRM of 0% and 20%, respectively </plain></SENT>
<SENT sid="13" pm="."><plain>Use of unrelated donors increased the risk of NRM only among patients with active disease </plain></SENT>
<SENT sid="14" pm="."><plain>FM and HSCT elicited long-term disease control in a significant fraction of this high-risk cohort </plain></SENT>
</text></document>